NASDAQ:NBRV Nabriva Therapeutics (NBRV) Stock Forecast, Price & News $0.45 +0.03 (+7.14%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.42▼$0.5050-Day Range$0.41▼$1.6252-Week Range$1.22▼$8.45Volume7,256 shsAverage Volume29,344 shsMarket Capitalization$14.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Nabriva Therapeutics (NASDAQ:NBRV) StockNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Read More NBRV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBRV Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comNabriva Therapeutics (NASDAQ:NBRV) Stock Passes Below Fifty Day Moving Average of $0.78September 30, 2023 | americanbankingnews.comNabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.comOctober 1, 2023 | Legacy Research (Ad)Elon Did It Again: This Could be Bigger than TeslaLove him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.September 25, 2023 | americanbankingnews.comReviewing Nabriva Therapeutics (NASDAQ:NBRV) & Mereo BioPharma Group (NASDAQ:MREO)September 22, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Nabriva Therapeutics (NASDAQ:NBRV)July 11, 2023 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesMay 26, 2023 | finance.yahoo.comNBRV - Nabriva Therapeutics plcFebruary 28, 2023 | marketwatch.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029October 1, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.February 25, 2023 | seekingalpha.comNBRV Nabriva Therapeutics plcJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Provides Corporate UpdateNovember 28, 2022 | marketwatch.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | markets.businessinsider.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisNovember 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | bizjournals.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | seekingalpha.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | finance.yahoo.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 10, 2022 | finance.yahoo.comMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | technews.tmcnet.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 7, 2022 | finance.yahoo.comNabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022September 15, 2022 | finance.yahoo.comNabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitSeptember 14, 2022 | finance.yahoo.comAll You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to BuySeptember 6, 2022 | finance.yahoo.comNabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 12, 2022 | marketwatch.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic FibrosisSee More Headlines Receive NBRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NBRV Company Calendar Last Earnings5/06/2021Today10/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBRV CUSIPN/A CIK1641640 Webwww.nabriva.com Phone(531) 649-2000Fax610-816-6639Employees39Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,190,000.00 Net Margins-148.11% Pretax Margin-144.78% Return on Equity-365.53% Return on Assets-135.81% Debt Debt-to-Equity Ratio0.12 Current Ratio0.85 Quick Ratio0.52 Sales & Book Value Annual Sales$35.59 million Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book4.50Miscellaneous Outstanding Shares32,015,000Free Float31,493,000Market Cap$14.41 million OptionableOptionable Beta1.53 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Colin Broom M.D. (Age 67)Director Comp: $40kMr. J. Christopher Naftzger BA (Age 56)Esq., J.D., Interim CEO, Gen. Counsel & Sec. Mr. Daniel Dolan (Age 46)Chief Financial Officer Key CompetitorsRenovoRxNASDAQ:RNXTCalciMedicaNASDAQ:CALCVBI VaccinesNASDAQ:VBIVFrequency TherapeuticsNASDAQ:FREQNightHawk BiosciencesNYSE:NHWKView All Competitors NBRV Stock - Frequently Asked Questions Should I buy or sell Nabriva Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" NBRV shares. View NBRV analyst ratings or view top-rated stocks. How have NBRV shares performed in 2023? Nabriva Therapeutics' stock was trading at $1.89 on January 1st, 2023. Since then, NBRV shares have decreased by 76.2% and is now trading at $0.45. View the best growth stocks for 2023 here. How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics plc (NASDAQ:NBRV) issued its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to analyst estimates of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%. Read the conference call transcript. When did Nabriva Therapeutics' stock split? Shares of Nabriva Therapeutics reverse split on the morning of Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Nabriva Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX). What is Nabriva Therapeutics' stock symbol? Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV." How do I buy shares of Nabriva Therapeutics? Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nabriva Therapeutics' stock price today? One share of NBRV stock can currently be purchased for approximately $0.45. How much money does Nabriva Therapeutics make? Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $14.41 million and generates $35.59 million in revenue each year. The biotechnology company earns $-57,190,000.00 in net income (profit) each year or ($19.20) on an earnings per share basis. How can I contact Nabriva Therapeutics? Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639. This page (NASDAQ:NBRV) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.